Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
Conclusion
This post hoc subanalysis revealed that although mild-to-moderately reduced renal function attenuated the glucose-lowering effects of luseogliflozin on peak postprandial glucose, it did not attenuate the effects of luseogliflozin on fasting glucose. These findings may explain the smaller increase in urinary glucose excretion in these patients relative to patients with normal renal function or normal-to-moderately reduced renal function. Further studies may be needed to examine these findings in large populations of patients with T2DM and reduced renal function.
Trial registration
JapicCTI-142548.
Funding
Taisho Pharmaceutical Co., Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | SGLT2 Inhibitors | Study